DS
EGRX

David Shaw’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

David Shaw’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-5,000
Closed -$267K – 3837
2017
Q4 		$267K Buy
+5,000
New +$278K ﹤0.01% 3289
2016
Q1 		– Sell
-10,200
Closed -$904K – 3842
2015
Q4 		$904K Buy
10,200
+200
+2% +$15.8K ﹤0.01% 2709
2015
Q3 		$740K Buy
+10,000
New +$832K ﹤0.01% 2815

Other funds holding EGRX

XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $984M AUM 72.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $522M AUM 26.29% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $49.3B AUM 36.45% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

David Shaw's EGRX Position: Q4 2024 in Review

David Shaw sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 54,625 shares — an estimated $204K sold.

David Shaw first reported a position in EGRX in Q3 2014 and held it in 34 quarters. The position peaked at $11.5M in Q4 2018. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

  • David Shaw reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • David Shaw sold 54,625 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $204K.
  • David Shaw first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2014 and held it in 34 quarters.
  • David Shaw's Eagle Pharmaceuticals, Inc. position peaked at $11.5M in Q4 2018.
  • 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on D.E. Shaw & Co's 13F filing for Q4 2024, filed 14 Feb 2025.